United States
ReCode Therapeutics, founded in 2015, is leading innovations in the biopharma sector with its focus on genetic medicines. Based in the United States, this clinical-stage company is setting a benchmark in the Biotechnology and Pharmaceutical industries.
With the slogan "Powering the next wave of genetic medicines through superior delivery," ReCode Therapeutics leverages its proprietary Selective Organ Targeting (SORT) Lipid Nanoparticle (LNP) platform to enhance precision drug delivery beyond traditional liver targets. This advanced delivery system positions ReCode as a frontrunner in the emerging field of mRNA and gene correction therapeutics.
The company secured a significant $15.00M grant investment on 01 November 2024, funded by the Cystic Fibrosis Foundation, underscoring confidence in its innovative approach. Investors seeking impactful entry into the genetic medicine market may find ReCode Therapeutics a promising opportunity poised for substantial growth and advancement.
